US4826826A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methylated chitosans and their use for the preparation of pharmaceutical compositions
Assignee: Texcontor
•
Filing: 1987-05-29
•
Granted: 1989-05-02
•
Expires: 2007-05-29
Abstract
Abstract Methylated chitosans are used for the preparation of pharmaceutical compositions having improved laxative properties over commonly used laxative. Said products are advantageouisly employed also in the preparation of ophtalmic solutions.
Inventors
- 👤 Franco Conti
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 20:37
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; C; C08; C08L; C08L5/00; C08L5/08; A61K31/716; A61K31/722; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0087; A61K9/0095; A61K9/08; C08B; C08B37/00; C08B37/0006; C08B37/0024; C08B37/0027; C08B37/003
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
57 words
A pharmaceutical composition for treatment of chronic constipation comprising a methylated chitosan selected from the group consisting of N-dimethylchitosan and O-methyl-N-dimethylchitosan which has a ratio of a number of methyl groups bound to oxygen to a number of available hydroxy groups between 0.2 and 1 in an amount effective against chronic constipation and a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
57 words
A pharmaceutical composition for treatment of chronic constipation comprising a methylated chitosan selected from the group consisting of N-dimethylchitosan and O-methyl-N-dimethylchitosan which has a ratio of a number of methyl groups bound to oxygen to a number of available hydroxy groups between 0.2 and 1 in an amount effective against chronic constipation and a pharmaceutically acceptable carrier.
Claim 3
Independent Claim
61 words
A method for treating chronic constipation which comprises orally administering to a patient suffering from constipation a methylated chitosan selected from the group consisting of N-dimethylchitosan and O-methyl-N-dimethylchitosan which has a ratio of a number of methyl groups bound to oxygen to a number of available hydroxy groups between 0.2 and 1 in an amount effective to produce a laxative effect.
Claim 4
Independent Claim
61 words
A method for treating chronic constipation which comprises orally administering to a patient suffering from constipation a methylated chitosan selected from the group consisting of N-dimethylchitosan and O-methyl-N-dimethylchitosan which has a ratio of a number of methyl groups bound to oxygen to a number of available hydroxy groups between 0.2 and 1 in an amount effective to produce a laxative effect.
Claim 5
Dependent Claim
18 words
The method of claim 2 wherein the amount of methylated chitosan administered is from 0.5 to 3 g/d.
Claim 6
Dependent Claim
17 words
The method of claim 2 wherein the methylated chitosan is administered in the form of solid tablets.
Claim 7
Dependent Claim
18 words
The method of claim 2 wherein the methylated chitosan is administered in the form of an aqueous solution.
Claim 8
Independent Claim
82 words
A method for treating keratoconjunctivitis sicca which comprises topically administering to a patient suffering from keratoconjunctivitis sicca an aqueous solution containing from 0.1% to 0.5% of a methylated chitosan selected from the group consisting of N-dimethylchitosan and O-methyl-N-dimethyl-chitosan which has a ratio of a number of methyl groups bound to oxygen to a number of available hydroxy groups between 0.2 and 1 and an opthalmically acceptable carrier wherein the methylated chitosan is administered in an amount effective to alleviate said keratoconjunctivitis sicca.
Claim 9
Independent Claim
82 words
A method for treating keratoconjunctivitis sicca which comprises topically administering to a patient suffering from keratoconjunctivitis sicca an aqueous solution containing from 0.1% to 0.5% of a methylated chitosan selected from the group consisting of N-dimethylchitosan and O-methyl-N-dimethyl-chitosan which has a ratio of a number of methyl groups bound to oxygen to a number of available hydroxy groups between 0.2 and 1 and an opthalmically acceptable carrier wherein the methylated chitosan is administered in an amount effective to alleviate said keratoconjunctivitis sicca.
Claim 10
Dependent Claim
58 words
An opthalmic composition for treatment of Keratoconjunctivitis sicca comprising a methylated chitosan selected from the group consisting of N-dimethylchitosan and O-methyl-N-dimethyl-chitosan which has a ratio of a number of methyl groups bound to oxygen to a number of available hydroxy groups between 0.2 and 1 in an amount effective against Keratoconjunctivitis sicca together with an ophthalmically acceptable carrier.
Claim 11
Dependent Claim
58 words
An opthalmic composition for treatment of Keratoconjunctivitis sicca comprising a methylated chitosan selected from the group consisting of N-dimethylchitosan and O-methyl-N-dimethyl-chitosan which has a ratio of a number of methyl groups bound to oxygen to a number of available hydroxy groups between 0.2 and 1 in an amount effective against Keratoconjunctivitis sicca together with an ophthalmically acceptable carrier.
References Cited (Backward Citations)
JPS5411955A
Cited
US4326532A
Cited
US4363801A
Cited
US4424346A
Cited
US4474769A
Cited
US4626287A
Cited
US4671823A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-01 | 1992-10-31 | 1993-05-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-01 | 1996-10-31 | 1997-05-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-01 | 2000-10-31 | 2001-05-02 | $7700.00 | Window Closed / Lapsed |